Kevin

“Maybe just back on BICAD, considering some of the on-the-ground dynamics that you're seeing this quarter being the first little quarter with BICAD, just maybe can you share your latest thoughts on how the potential opportunity, the peak opportunity in PWS may be, whether your thoughts now are a bit more refined on…”

“Just as you think more about lupus, the heterogeneity of the disease, and just maybe some of the challenges prior agents have had and novel ones which could be approved in the next few years.”

“So maybe just one on the debut opportunity in Japan, can you remind us maybe what the phase three trial design is there and what efficacy endpoints those regulators might require, and then just what the addressable Rett syndrome population is in Japan?”

“Maybe following up on the Sirolimus study, can you talk a bit about your new N of 20 Phase 4 enhanced study of patients receiving alavetus and Sirolimus in the real world.”

“So we just had a couple on the proposed survival in the study.”